

Clinical Trial Protocol

Iranian Registry of Clinical Trials

30 Jun 2026

Comparison of efficacy of short-acting insulin (Regular) manufactured by Ronak Daru (Ronulin ®) with manufactured by Exir (Lansulin®) in reducing blood sugar after meals in patients with type 2 diabete

Protocol summary

Summary

The main goal of study is Comparison of efficacy of short-acting insulin (Regular) manufactured by Ronak Daru (Ronulin ®) with manufactured by Exir (Lansulin®) in reducing blood sugar after meals in patients with type 2 diabetes. Study is randomized, single centre, cross-over, and not blind that was done on 40 patients with type 2 diabetes that treated with insulin with or without oral agent. This patients treat with less than 1.4 U/kg/d well, is more than 18 years old, isn't obese, and don't have any complication. We take Informed consent from them. Duration of study is 3 months for any group (first 3 months for Ronalin or Lansulin and then inverse). Dosage of regular insulin or NPH insulin is as before. NPH insulin of two groups is Lansulin. Patients is visited by physician during the study every 2 weeks and is checked for FBS, 2 hr postprandial, and acute complications such as hypoglycemia or hyperglycemia. The primary outcome is HbA1c after survey. The secondary outcome is weight and insulin dosage difference and acute complications(hypoglycemia and hyperglycemia).

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2013040812938N1**

Registration date: **2013-04-24, 1392/02/04**

Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2013-04-24, 1392/02/04

Registrant information

Name

Zahra Kourorian

Name of organization / entity

Ronak Daru Company of Pharmacy

Country

Iran (Islamic Republic of)

Phone

+98 21 8898 9441

Email address

zkourorian@irimc.org

Recruitment status

Recruitment complete

Funding source

Ronak Daru Company of pharmacy

Expected recruitment start date

2012-12-21, 1391/10/01

Expected recruitment end date

2013-04-21, 1392/02/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison of efficacy of short-acting insulin (Regular) manufactured by Ronak Daru (Ronulin ®) with manufactured by Exir (Lansulin®) in reducing blood sugar after meals in patients with type 2 diabete

Public title

Insulin efficacy in diabetes management

Purpose

Health service research

Inclusion/Exclusion criteria

inclusion criteria: 1-diabetic patients type 2 treated with insulin with or without oral drug. 2-100mg/dl< FBS <250mg/dl. 3-7< HbA1c< 9. 4-male or female with age

> 18 years old*. 5-BMI≤30 kg/m². *We have enrolled patients with age more than 18 years, according to reference 17, 18, 19, and 20. Age don't be considered as a confounding factor because study has randomized design. exclusion criteria: 1- microvascular and macrovascular complications. 2- hypoglycemia(BS<45mg/dl) or hyperglycemia(BS>250mg/dl). 3-pregnancy or Breastfeeding. 4- use of glucocorticoides or any drug that lead hyperglycemia. 5- uncontrolled HTN (BP>180/105). 6-insulin allergy. 7-use of more than 1.4 U/kg/d insulin. 8-نرمال Cr>2 mg/dl or LFT>twofold normal range. 9- Patient withdrew from the study.

Age

From **18 years** old to **70 years** old

Gender

Both

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: **40**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Not used

Assignment

Crossover

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Baqiyatallah University of Medical Sciences

Street address

Molla Sadra Ave, Vanak Sq.

City

Tehran

Postal code

Approval date

2012-10-17, 1391/07/26

Ethics committee reference number

340/22/س

Health conditions studied

1

Description of health condition studied

Diabete

ICD-10 code

E10,E11,E1

ICD-10 code description

Diabetes mellitus

Primary outcomes

1

Description

mean of HbA1c in the end of study

Timepoint

HbA1c levels before and after of any intervation

Method of measurement

at before and after of intervation by laboratory with HPLC assay

Secondary outcomes

1

Description

hypoglycemia

Timepoint

during study

Method of measurement

Bionime Glucometer

2

Description

weight changes

Timepoint

before and after of intervation

Method of measurement

scale

3

Description

hyperglycemia

Timepoint

during study

Method of measurement

Bionime glucometer

4

Description

insulin dosage

Timepoint

during study

Method of measurement

unit

Intervention groups

1

Description

control: manufactured by Exir (Lansulin®)

Category

Treatment - Drugs

2**Description**

Ronak Daru (Ronulin ®)

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Chemical Injury Research Center

Full name of responsible person

Dr nahid Khalili

Street address

Baqiyatalla Hospital, Molla Sadra Ave, Vanak Sq

City

Tehran

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Ronak Daru Company of pharmacy

Full name of responsible person

Dr Zahra Kororian

Street address

Fatemi Ave, Hashtbehesht Str, Ardeshir Str, No 10/3

City

Tehran

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Ronak Daru Company of pharmacy

Proportion provided by this source

100

Public or private sector*empty***Domestic or foreign origin***empty***Category of foreign source of funding***empty***Country of origin****Type of organization providing the funding***empty***Person responsible for general inquiries****Contact****Name of organization / entity**

Chemical Injury Research Center

Full name of responsible person

Dr yunes Panahi

PositionAssociate of Professor/head of Chemical Injury
Research Center**Other areas of specialty/work****Street address**Baqiyatallah University of Medical Sciences, Molla
Sadra Ave, Vanak Sq**City**

Tehran

Postal code**Phone**

+98 21 8821 1524

Fax**Email**

yunespanahi@yahoo.com

Web page address**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Internal Medicine Department

Full name of responsible person

Dr nahid Khalili

Position

Assistant of Professor

Other areas of specialty/work**Street address**Baqiyatallah University of Medical Sciences, Molla
Sadra Ave, Vanak Sq**City**

Tehran

Postal code**Phone**

+98 21 8126 3988

Fax

+98 21 8126 3989

Email

nkhalili09@gmail.com

Web page address**Person responsible for updating data****Contact****Name of organization / entity**

Ronak Daru Company of pharmacy

Full name of responsible person

Dr Zahra Kourorian

Position

General Physician/Manager of Clinical trials

Other areas of specialty/work**Street address**

Fatemi Ave, Hashtbehesht Str, Ardeshir Str, No 10/3

City

Tehran

Postal code

1414713461

Phone

+98 21 8898 9441

Fax

+98 88989443

Email

zkourorian@razi.tums.ac.irzkourorian@irimc.org

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty